Notably, UCAR T 123, composed of allogeneic T cells from healthy donors expressing anti-CD123 CAR and edited using transcription activator-like effector nuclease (TALEN), presents a promising candidate for treating relapsed/refractory AML and BPDCN (Figure 2) [67]. This evidence concerns the gene IL3RA and acute myeloid leukemia.